Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188489 | 0.83 | HTR7 (0.44) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E | |
| SCHEMBL27639452 | 0.83 | HTR1B (0.43) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E | |
| SCHEMBL188299 | 0.83 | HTR7 (0.44) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E | |
| SCHEMBL188778 | 0.81 | KDM4E (0.53) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E | |
| SCHEMBL13948841 | 0.80 | HRH1 (0.63) | CYP1A2CYP2D6CYP2C19HTR1BHRH1 | |
| SCHEMBL6017158 | 0.80 | KDM4E (0.48) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E | |
| SCHEMBL27869504 | 0.80 | ALDH1A1 (0.44) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E | |
| SCHEMBL2937356 | 0.79 | TSHR (0.37) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL189114 | 0.75 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E | |
| SCHEMBL27699412 | 0.75 | ALDH1A1 (0.46) | CYP1A2CYP2D6CYP2C19HTR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | CYP1A2 1318/4885CYP2D6 1209/4885CYP2C19 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.